

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
08/648,092	06/21/1996	JOHNSTON W. MCAVOY	UNSYD-39709	8661
24201	7590 08/06/20	33		
FULWIDER PATTON LEE & UTECHT, LLP HOWARD HUGHES CENTER 6060 CENTER DRIVE			EXAMINER	
			FAY, ZOH	IREH A
TENTH FLOOR LOS ANGELES, CA 90045			ART UNIT	PAPER NUMBER
	,		1614	1, 2
			DATE MAILED: 08/06/2003	46

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
		MCAVOY ET AL.				
Office Action Summary	08/648,092					
omce Action Gammary	Examiner	Art Unit				
The MAILING DATE of this communication app	Zohreh Fay ears on the cover sheet with the c	1614 orrespondence address				
Period for Reply		••••••••••••••••••••••••••••••••••••••				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	66(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) day fill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on						
	· is action is non-final.					
3) Since this application is in condition for alloward closed in accordance with the practice under a	nce except for formal matters, pr					
Disposition of Claims						
4) Claim(s) 14-38 is/are pending in the application						
·	4a) Of the above claim(s) <u>29-33</u> is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
	Claim(s) 14-28 and 34-38 is/are rejected.					
7) Claim(s) is/are objected to.	r alastian requirement					
8) Claim(s) are subject to restriction and/or Application Papers	r election requirement.	•				
9) The specification is objected to by the Examine	r.					
10) The drawing(s) filed on is/are: a) accept		miner.				
Applicant may not request that any objection to the						
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12)☐ The oath or declaration is objected to by the Ex	aminer.					
Priority under 35 U.S.C. §§ 119 and 120	•					
13)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents	s have been received.					
2. Certified copies of the priority documents	s have been received in Applicati	ion No				
3. ☑ Copies of the certified copies of the prior application from the International Bu * See the attached detailed Office action for a list	reau (PCT Rule 17.2(a)).	-				
14) Acknowledgment is made of a claim for domesti	c priority under 35 U.S.C. § 119(e) (to a provisional application).				
 a) The translation of the foreign language pro 15) Acknowledgment is made of a claim for domest 						
Attachment(s)						
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Moritage of Draftsperson's Patent Drawing Review (PTO-948) Moritage of Draftsperson's Patent Drawing Review (PTO-1449) Paper No(s) 4	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)				
S. Patent and Trademark Office						



Art Unit: 1614

Claims 14-38 are presented for examination.

The amendments and remarks filed on February 10, 2003 have been received and entered.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 14-18 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 14-18 are indefinite as to the expression "cataract-like disorders", which fails to set forth the scope of the disorders applicant intends to get protection for.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 14-28 and 34-38 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims of the instant application are drawn to "the preventing or controlling cataract or catarct-like disorders'. The support in the specification shows the treatment or inhibition of cataract induced by the growth factor by the using the claimed compound, a growth factor antagonist. There is no support for the prevention of cataract in general, and there is no support for the





Art Unit: 1614

prevention of "cataract- like disorders" by using the inhibitors of TGFB. In the absence of some understanding of the disease to be treated and which, if any, antagonist could be used to treat said disease, the artisan would not have accepted that the applicant was in possession of the claimed method.

Claims 14-23 and 34-38 are rejected under 35 U.S.C. 102 (b) as being anticipated by WO 92/17206. The WO Patent teaches the use of the claim-designated inhibitors of TGFB, at the claimed concentrations for the treatment of wounds to inhibit scar tissue formation. Such use would inherently prevents cataract formation. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zohreh. Fay whose telephone number is (703) 308-4604. The examiner can normally be reached on 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Z.F August 5, 2003 ZOHILEH YAY PHIMARY EXAMINER GROUP 1200